GO
Loading...

Express Scripts Holding Co

More

  • Early Glance: Drug Benefits companies Thursday, 26 Feb 2015 | 10:35 AM ET

    NEW YORK— Shares of some top drug benefits companies are mixed at 10 a.m.:. CVS Health Corp. rose$. 24 or. 2 percent, to $103.68. Express Scripts Holding Co. fell$. 34 or. 4 percent, to $84.75.

  • Midday Glance: Drug Benefits companies Wednesday, 25 Feb 2015 | 1:18 PM ET

    NEW YORK— Shares of some top drug benefits companies are mixed at 1 p.m.:. CVS Health Corp. rose$. 50 or. 5 percent, to $103.86. Express Scripts Holding Co. fell $2.44 or 2.8 percent, to $85.18.

  • Early Glance: Drug Benefits companies Wednesday, 25 Feb 2015 | 11:23 AM ET

    NEW YORK— Shares of some top drug benefits companies are down at 10 a.m.:. CVS Health Corp. fell$. 15 or. 1 percent, to $103.21. Express Scripts Holding Co. fell $2.00 or 2.3 percent, to $85.62.

  • Final Glance: Drug Benefits companies Tuesday, 24 Feb 2015 | 6:02 PM ET

    NEW YORK— Shares of some top drug benefits companies were up at the close of trading:. CVS Health Corp. rose$. 10 or. 1 percent, to $103.36. Express Scripts Holding Co. rose$. 90 or 1.0 percent, to $87.62.

  • Midday Glance: Drug Benefits companies Tuesday, 24 Feb 2015 | 1:17 PM ET

    NEW YORK— Shares of some top drug benefits companies are mixed at 1 p.m.:. CVS Health Corp. fell$. 04 or percent, to $103.23. Express Scripts Holding Co. rose$. 71 or. 8 percent, to $87.43.

  • Early Glance: Drug Benefits companies Tuesday, 24 Feb 2015 | 11:24 AM ET

    NEW YORK— Shares of some top drug benefits companies are down at 10 a.m.:. CVS Health Corp. fell$. 47 or. 5 percent, to $102.79. Express Scripts Holding Co. fell$. 15 or. 2 percent, to $86.57.

  • Final Glance: Drug Benefits companies Monday, 23 Feb 2015 | 6:04 PM ET

    NEW YORK— Shares of some top drug benefits companies were up at the close of trading:. CVS Health Corp. rose$. 56 or. 5 percent, to $103.26. Express Scripts Holding Co. rose$. 64 or. 7 percent, to $86.72.

  • ST. LOUIS— Shares of Express Scripts Holding Co. traded higher in extended trading Monday after the nation's largest pharmacy benefit manager reported better-than-expected quarterly results. Express Scripts earned $581.8 million, or 79 cents per share, compared with $501.9 million, or 63 cents per share. Express Scripts forecast a profit of $1.07 to $1.11...

  • US stocks close near highs ahead of Yellen testimony Monday, 23 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange Feb. 20, 2015.

    U.S. stocks pulled back from Friday's records to close narrowly mixed ahead of Fed Chair Janet Yellen's remarks over the next two days.

  • Midday Glance: Drug Benefits companies Monday, 23 Feb 2015 | 1:20 PM ET

    NEW YORK— Shares of some top drug benefits companies are up at 1 p.m.:. CVS Health Corp. rose$. 56 or. 5 percent, to $103.26. Express Scripts Holding Co. rose$. 37 or. 4 percent, to $86.45.

  • Early Glance: Drug Benefits companies Monday, 23 Feb 2015 | 10:40 AM ET

    NEW YORK— Shares of some top drug benefits companies are down at 10 a.m.:. CVS Health Corp. fell$. 05 or percent, to $102.65. Express Scripts Holding Co. fell$. 08 or. 1 percent, to $86.00.

  • Wall Street uneasy after Greece deal; Yellen eyed Monday, 23 Feb 2015 | 8:25 AM ET
    Janet Yellen, Chair of the Federal Reserve.

    U.S. stock index futures signaled a lower open on Monday as uncertainty surrounded Greece's deal with its euro zone creditors.

  • Cramer's game plan: Expect major news on this Friday, 20 Feb 2015 | 6:15 PM ET
    Spanish Finance Minister Luis de Guindos, left, talks with Greek Finance Minister Yanis Varoufakis at a euro zone finance ministers meeting to discuss Athens' plans to reverse austerity measures, in Brussels, Feb. 20, 2015.

    With the Dow soaring to new highs, Jim Cramer is ready to do some buying in case the euphoria wears off.

  • US still the place to be: Delphi's Scott Black Friday, 20 Feb 2015 | 3:47 PM ET
    Traders work on the floor of the New York Stock Exchange Feb. 20, 2015.

    U.S. stocks are the place to be right now, Delphi's Scott Black said Friday on CNBC. Here's where he's putting his money.

  • Buffett's Berkshire builds Deere stake, dumps Exxon Wednesday, 18 Feb 2015 | 7:19 AM ET
    A John Deere 8600 tractor is displayed on opening day of the World Ag Expo on February 10, 2015 in Tulare, Calif.

    Warren Buffett's Berkshire Hathaway disclosed a 5 percent stake in Deere & Co. and said it shed a $3.74 billion investment in Exxon Mobil.

  • NEW YORK, Feb 17- Warren Buffett's Berkshire Hathaway Inc on Tuesday disclosed a 5 percent stake in agricultural equipment maker Deere& Co and said it shed a $3.74 billion investment in oil company Exxon Mobil Corp as oil prices plunged. The changes were among several that Berkshire made in its common stock investments in the fourth quarter, according to a U.S....

  • Drug price wars 'drive value': Medical exec Friday, 6 Feb 2015 | 5:21 PM ET
    Hepatitis C sufferers and supporters hold placards during a demonstration outside of US laboratory Gilead Sciences office in Madrid on February 5, 2015.

    Price cuts, which may hurt pharmaceutical margins, are fundamentally better for consumers, said Dr. Steve Miller of Express Scripts.

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.